News & Media

Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development

Press Releases · August 10, 2022

Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development

Prellis Biologics Announces Collaboration with Sanofi

Press Releases · March 22, 2022

Prellis Biologics Announces Collaboration with Sanofi

Press Release: Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb

Press Releases · January 13, 2022

Press Release: Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb

Prellis Biologics raises $14.5M, debuts a “human immune system” in a dish

Press Releases · December 15, 2021

Prellis Biologics raises $14.5M, debuts a “human immune system” in a dish

Prellis Biologics, Inc. Generates 300 Human Antibodies That Bind the SARS-CoV2 Virus; Pursues Development of a Treatment and Preventative Therapy for COVID-19 Infection

Press Releases · May 19, 2020

Prellis Biologics, Inc. Generates 300 Human Antibodies That Bind the SARS-CoV2 Virus; Pursues Development of a Treatment and Preventative Therapy for COVID-19 Infection

Prellis Biologics Pursues Bioprinted Lymph Nodes for Production of COVID-19 Antibodies

Press Releases · May 7, 2020

Prellis Biologics Pursues Bioprinted Lymph Nodes for Production of COVID-19 Antibodies

Prellis Biologics raises $8.7 Million, reports progress in 3D holographic tissue printing

Press Releases · July 30, 2019

Prellis Biologics raises $8.7 Million, reports progress in 3D holographic tissue printing